Managing type 2 diabetes and obesity has historically been a challenge for patients and healthcare providers alike. While a range of treatments exist, many fall short in addressing both conditions simultaneously. Enter tirzepatide, a novel medication that’s reshaping how these metabolic diseases are treated. Although semaglutide made headlines as a leading GLP-1 receptor agonist, tirz... https://biotechlabzsupply.com/